Allogenic adipose-derived mesenchymal stem cell therapy - Regeneus ltd

Drug Profile

Allogenic adipose-derived mesenchymal stem cell therapy - Regeneus ltd

Alternative Names: PRG; Progenza

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneus ltd
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 24 Mar 2017 Regeneus completes the phase I STEP trial in Osteoarthritis in Australia (Intra-articular) (ACTRN12615000439549)
  • 29 Dec 2016 Progenza licensed to AGC Asahi Glass in Japan
  • 29 Dec 2016 Regeneus in collaboration with AGC Asahi Glass plans a phase II trial for Osteoarthritis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top